Search | Clinical Trials Finder

Conditions: Ovarian Cancer
Interventions: Doxil, Avastin; Drug
Lead sponsor: New Mexico Cancer Research Alliance; Other
Eligibility: 18 Years and older · Female only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 3
States / cities: Albuquerque, New Mexico • Santa Fe, New Mexico • New York, New York

Conditions: Colorectal Neoplasms, Colon Cancer, Rectal Cancer, Anal Cancer
Interventions: Bevacizumab; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Gastric Cancer
Interventions: 5-Fluorouracil, Ipatasertib, Leucovorin, Oxaliplatin, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 3
States / cities: Los Angeles, California • Boston, Massachusetts • Houston, Texas

Conditions: HIV Infection
Interventions: Nutropin, Oral Glucose Tolerance Test, Dual Energy X-ray Absorptiometry (DEXA), Computed Tomography (CT) Scan; Drug · Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 3
States / cities: Dallas, Texas

Conditions: Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Interventions: Paclitaxel,, Bevacizumab, Cisplatin, Olaparib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 2 more

Conditions: Colorectal Cancer Stage II, Colorectal Cancer Stage III
Interventions: RO7198457 intravenous (IV), Observational group (no intervention); Drug · Other
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 15
States / cities: Greenbrae, California • Indianapolis, Indiana • Minneapolis, Minnesota + 12 more

Conditions: Non-Small Cell Lung Cancer (NSCLC), Small-Cell Lung Cancer (SCLC)
Interventions: Blood Draw; Other
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 945 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 23
States / cities: Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 20 more

Conditions: Influenza
Interventions: Baloxavir, Placebos; Drug
Lead sponsor: Bassett Healthcare; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 3
States / cities: Springfield, Massachusetts • Cooperstown, New York • Portland, Oregon

Conditions: Breast Cancer
Interventions: Ipatasertib, Fulvestrant, Aromatase Inhibitor, Palbociclib; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Glaucoma
Interventions: Ranibizumab, Mitomycin (MMC); Drug
Lead sponsor: Wills Eye; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Metastatic Breast Cancer
Interventions: Trastuzumab plus Pertuzumab, Hormonal Therapy with Anastrozole and Fulvestrant, Chemotherapy with Eribulin; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 60 Years and older · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Radiation Retinopathy
Interventions: 0.5 mg ranibizumab, Targeted Retinal Photocoagulation (TRP); Drug · Procedure
Lead sponsor: Greater Houston Retina Research; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 4
States / cities: Dallas, Texas • Houston, Texas • Katy, Texas + 1 more

Conditions: Ocular Graft vs Host Disease, Dry Eye
Interventions: rhDNase I, Vehicle; Drug
Lead sponsor: University of Illinois at Chicago; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Diabetic Macular Edema
Interventions: RO7446603, Aflibercept, Faricimab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 388 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 70
States / cities: Phoenix, Arizona • Springdale, Arkansas • Campbell, California + 60 more

Conditions: Metastatic Prostate Cancer
Interventions: Atezolizumab, Abiraterone, Prednisone, GnRH analog, Stereotactic Body Radiotherapy (SBRT), Enzalutamide, Follow up; Drug · Radiation · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 8
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Healthy Volunteer
Interventions: GDC-0032 Phase III Tablet, GDC-0032 Tablet, GDC-0032 Capsule; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Head and Neck Cancer
Interventions: Erlotinib, Docetaxel, Radiation Therapy; Drug · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hemophilia A
Interventions: Nuwiq (low dose protocol), HEMLIBRA, Nuwiq (Atlanta protocol); Drug
Lead sponsor: Emory University; Other
Eligibility: Up to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 8
States / cities: Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 5 more

Conditions: Head and Neck Cancer
Interventions: Erlotinib; Drug
Lead sponsor: Geisinger Clinic; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Danville, Pennsylvania

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Male only
Enrollment: 5,290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1990 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Estrogen Receptor Negative Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Triple Negative Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer, Triple-negative Breast Cancer
Interventions: cisplatin, laboratory biomarker analysis, pharmacological study, dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI, GDC -0941; Drug · Other · Procedure
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 16
States / cities: Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 13 more

Conditions: Colorectal Carcinoma Metastatic in the Liver
Interventions: yttrium-90 radioembolization; Combination Product
Lead sponsor: Brown University; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Macular Degeneration, Age-Related, Geographic Atrophy
Interventions: Galegenimab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 60 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 48
States / cities: Bakersfield, California • Encino, California • Fullerton, California + 43 more

Conditions: Pancreatic Cancer
Interventions: Atezolizumab, RO7198457, mFOLFIRINOX; Drug · Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Search by objective public record fields.

Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA)

Avastin/[18-F]-5-fluorouracil PET/CT Imaging Feasibility Project

A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

The Use of Nutropin Depot in HIV-infected Adult Males

Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer

Prospective Clinicogenomic Program

COmbination Therapy With Baloxavir and Oseltamivir 1 for Hospitalized Patients With Influenza (The COMBO Trial 1)

AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)

Lucentis Versus Mitomycin C During Glaucoma Surgery

1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.

Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy.

rhDNase Eye Drops in Patients With Ocular Graft-Vs.-Host Disease

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema

Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

A Study to Evaluate the Effect of Particle Size, Formulation and Food on the Pharmacokinetics of GDC-0032 in Healthy Volunteers

Erlotinib and Docetaxel With Concomitant Boost Radiation Therapy (XRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)

Emicizumab PUPs and Nuwiq ITI Study

Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer

Molecular Studies and Clinical Correlations in Human Prostatic Disease

GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer

Y-90, Capecitabine, and Atezolizumab for Oligometastatic CRC

A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery